- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT03767595
ProACT Post-Godkjenningsstudie
Studie etter godkjenning av ProACT™ justerbar kontinensterapi for menn
The ProACT Post Approval Study is a 5-year prospective, open-label, multi-center study designed to evaluate the long-term incidence of urethral stricture and device erosion after ProACT implantation. In addition, the study will evaluate whether treatment with ProACT affects clinical outcomes after subsequent SUI therapies.
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Studietype
Registrering (Antatt)
Fase
- Ikke aktuelt
Kontakter og plasseringer
Studiekontakt
- Navn: Matt Kelly, PhD
- Telefonnummer: 6124698882
- E-post: usmtk@coloplast.com
Studer Kontakt Backup
- Navn: Lisa DRAPER
- E-post: usldr@coloplast.com
Studiesteder
-
-
California
-
Los Angeles, California, Forente stater, 90033
- Rekruttering
- University of Southern California
-
Ta kontakt med:
- Julissa Morales
- E-post: julissa.morales@med.usc.edu
-
Hovedetterforsker:
- Jeffrey Loh-Doyle, MD
-
Santa Barbara, California, Forente stater, 93110
- Rekruttering
- Sutter Health
-
Ta kontakt med:
- Morgan Caldwell-Holden
- E-post: morgan.caldwell-holden@sutterhealth.org
-
Ta kontakt med:
- Megan Martinez
- E-post: megan.martinez@sutterhealth.org
-
Hovedetterforsker:
- Scott Tobis, MD
-
-
Colorado
-
Denver, Colorado, Forente stater, 80045
- Rekruttering
- University of Colorado
-
Ta kontakt med:
- Andrea Pina
- E-post: andrea.pinalimones@cuanschutz.edu
-
Hovedetterforsker:
- Brian Flynn, MD
-
Underetterforsker:
- Nate Coddington, MD
-
-
Florida
-
Gainesville, Florida, Forente stater, 32610
- Rekruttering
- University of Florida
-
Ta kontakt med:
- John Marks, DHSc, CCRP
- Telefonnummer: 352-273-5618
- E-post: John.Marks@urology.ufl.edu
-
Hovedetterforsker:
- Lawrence Yeung, MD
-
Hialeah, Florida, Forente stater, 33016
- Rekruttering
- Urological Research Network Corp
-
Hovedetterforsker:
- Edward Gheiler, MD
-
Ta kontakt med:
- Isabel Lopez
- E-post: isabel@besturology.net
-
-
Georgia
-
Atlanta, Georgia, Forente stater, 30322
- Rekruttering
- Emory University
-
Hovedetterforsker:
- Lindsey Hartsell, MD
-
Ta kontakt med:
- Nahir Imtiaz
- E-post: sbimtia@emory.edu
-
-
Kansas
-
Kansas City, Kansas, Forente stater, 66103
- Rekruttering
- University of Kansas Medical Center
-
Ta kontakt med:
- Kirk Redger, MD
- Telefonnummer: 913-588-1227
- E-post: kredger@kumc.edu
-
-
Michigan
-
Ann Arbor, Michigan, Forente stater, 48109
- Rekruttering
- University of Michigan
-
Ta kontakt med:
- Nailah Henry
- E-post: hnailah@med.umich.edu
-
Hovedetterforsker:
- Bahaa Malaeb, MD
-
-
Minnesota
-
Saint Cloud, Minnesota, Forente stater, 56303
- Rekruttering
- CentraCare- St. Cloud
-
Ta kontakt med:
- Andrew Windsperger, MD
- Telefonnummer: 320-229-4547
- E-post: andrew.windsperger@centracare.com
-
-
Nebraska
-
Omaha, Nebraska, Forente stater, 68124
- Rekruttering
- CHI Health Research
-
Hovedetterforsker:
- Michael Feloney, MD
-
Ta kontakt med:
- Jan Mitchell
- E-post: jan.mitchell@commonspirit.org
-
-
Pennsylvania
-
Allentown, Pennsylvania, Forente stater, 18103
- Rekruttering
- Lehigh Valley Health Network
-
Ta kontakt med:
- Megan McGonagle, MSN, RN, PCCN
- E-post: Megan.mcgonagle@jefferson.edu
-
Hovedetterforsker:
- Matthew Loecher, MD
-
Pittsburgh, Pennsylvania, Forente stater, 15212
- Rekruttering
- Allegheny Health Network
-
Ta kontakt med:
- Rachel Reading
- E-post: rachel.reading@ahn.org
-
Ta kontakt med:
- Tibetha Santucci
- E-post: tibetha.santucci@ahn.org
-
Hovedetterforsker:
- Kiran Sury, MD
-
-
Texas
-
Arlington, Texas, Forente stater, 76017
- Rekruttering
- Urology Partners of North Texas Research Institute
-
Hovedetterforsker:
- Keith Xavier, MD
-
Ta kontakt med:
- Grace Yoon
- E-post: gyoon@folioclinicalresearch.com
-
McAllen, Texas, Forente stater, 78504
- Rekruttering
- DHR Health Institute for Research and Development
-
Hovedetterforsker:
- Henry Ruiz, MD
-
Ta kontakt med:
- Clarisa Medina
- E-post: c.medina@dhrhealth.com
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
-
Subject is a male of at least 50 years of age.
-
Subject demonstrates stress urinary incontinence.
-
Subject has undergone a radical prostatectomy, transurethral resection of the prostate, or other prostate surgery.
-
Subject is willing and able to undergo surgical implantation of ProACT devices.
-
Subject is willing and able to comply with study-required
follow-up activities, including annual telephonic follow -up interviews, for a period of 5 years from their date of initial implantation. This includes compliance even after possible explant of ProACT devices and/or possible implantation of subsequent therapies.
-
Subject is willing and able to sign the approved informed consent.
-
Subject has two positive 24-hour pad weight tests (greater than or equal to 8 gram pad weight increase demonstrated in two 24-hour pad weight tests).
-
Subject has a negative urine culture.
-
Subject has no known urogenital malignancy, other than previously treated prostate cancer.
-
Subject meets ONE of the following criteria:
- Baseline Prostate-Specific Antigen (PSA) of less than or equal to 2.5ng/mL;
- Baseline PSA > 2.5ng/mL and less than or equal to 10 ng/mL AND free PSA greater than or equal to 25% of total PSA;
-
Physician determines subject to be a suitable surgical candidate.
Exclusion Criteria:
- Subject has an existing urethral stricture, a history of any urethral strictures, or has ever had a urethrotomy.
- Subject has undergone prostate surgery or any anti-incontinence surgery within the last 12 months.
- Subject has an artificial urinary sphincter or any components of a previously implanted artificial urinary sphincter in vivo.
- Subject has undergone radiation therapy in the prostatic area within the last 12 months.
- Subject has untreated or unsuccessfully treated detrusor instability or over-activity.
- Subject has an atonic bladder.
- Subject had, presently has, or is suspected of having bladder cancer.
- Subject has untreated or unsuccessfully treated bladder stones.
- Subject has detrusor sphincter dyssynergia.
- Subject has known hemophilia or a bleeding disorder.
- Subject has a known severe contrast solution allergy (e.g., anaphylaxis, cardiac, or respiratory arrest).
- Subject has insulin-dependent diabetes that is uncontrolled or not controllable, as indicated by an A1c test result of = 6.5%.
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: N/A
- Intervensjonsmodell: Enkeltgruppeoppdrag
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: ProACT Adjustable Continence Therapy for Men
Patients implanted with ProACT Adjustable Continence Therapy for Men |
The ProACT therapy consists of two small, adjustable silicone balloons connected with tubing to a port. During a minimally invasive outpatient procedure, the balloons are surgically placed in the area where the prostate was removed or resected. |
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Urethral Strictures
Tidsramme: 5 years
|
Cumulative incidence of ProACT-related clinically relevant urethral strictures over 5 years of follow up. |
5 years
|
|
Device Erosions
Tidsramme: 5 years
|
Cumulative incidence of ProACT device erosions over 5 years of follow-up. |
5 years
|
|
Incontinence Quality of Life Questionnaire (I-QoL)
Tidsramme: 5 years
|
Results on Validated Incontinence Quality of Life Questionnaire |
5 years
|
Andre resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Effect of ProACT on Subsequent Stress Urinary Incontinence(SUI) Therapy
Tidsramme: 5 years
|
This data will be collected with a "Post ProACT Explant Subsequent Therapy Questionnaire". This questionnaire will ask 3 questions regarding the ProACT therapy
The scale for each question is 0-1. 0 Meaning no effect (a "No" response on the questionnaire) and 1 being some effect ("Yes" response on the questionnaire). No effect (0) on subsequent SUI therapies is the better outcome. |
5 years
|
Samarbeidspartnere og etterforskere
Sponsor
Etterforskere
- Studieleder: Philip Johnson, PhD, Uromedica, Inc. / Coloplast, Corp
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Antatt)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
- Urogenitale sykdommer
- Mannlige urogenitale sykdommer
- Urologiske sykdommer
- Kvinnelige urogenitale sykdommer
- Kvinnelige urogenitale sykdommer og graviditetskomplikasjoner
- Vannlatingsforstyrrelser
- Nedre urinveissymptomer
- Urologiske manifestasjoner
- Urininkontinens
- Patologiske tilstander, tegn og symptomer
- Tegn og symptomer
- Urininkontinens, stress
Andre studie-ID-numre
- PAS001
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
produkt produsert i og eksportert fra USA
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .